Tracking Psychedelic Legislative Reform In the United States: A State-Level Policy Analysis, 2019–2025

Background and Purpose:
Psychedelic medicines (e.g., psilocybin, MDMA) remain Schedule I substances under U.S. federal law despite expanding clinical research and growing state-level reform. In the absence of federal action, states have become primary drivers of policy innovation, creating a rapidly evolving and fragmented landscape for access to emerging behavioral health interventions. A 2022 review in JAMA Psychiatry characterized early legislative trends and proposed a model of psychedelic legalization based on cannabis policy trajectories. Since then, substantial policy activity—including new regulatory frameworks, increased legislative volume, and targeted initiatives (e.g., for veterans)—necessitates updated analysis. For social work, these shifts raise critical questions about how access to emerging treatments is governed, who benefits from policy change, and how reforms align with principles of equity and the common good. This study examines trends in U.S. state-level psychedelic reform from 2019–2025 and evaluates whether legalization is following patterns observed in cannabis policy.

Methods:
We compiled and de-duplicated a comprehensive database of state legislative and ballot initiatives related to psychedelic reform from 2019–2025 using a 50-state legislative search engine, Ballotpedia, and supplementary sources. Bills were coded for substance type, regulatory framework (e.g., decriminalization, medical access programs, research initiatives), professional involvement, funding provisions, target populations, and “trigger law” status. Descriptive analyses were conducted to characterize national trends, geographic spread, and enactment rates. Observed legalization patterns were compared to projections from prior cannabis-based policy models.

Results:
Of 862 potentially relevant bills identified, 243 (28%) met inclusion criteria. By 2026, 78% of U.S. states had considered psychedelic-related legislation, reflecting substantial geographic expansion. A total of 44 bills (16%) were enacted across 23 states, with annual enactment rates ranging from 10% to 19%. Legislative activity has increased markedly since 2022, both in volume and scope. Psilocybin dominated proposals (approximately 90%), with emerging state-regulated access models in Oregon, Colorado, and New Mexico. Notably, 27% of bills specifically targeted veterans or first responders, with these bills demonstrating higher enactment rates compared to general population proposals. While policy innovation is expanding, the pace of formal legalization remains slower than predicted by cannabis-based models, with only a small number of states establishing comprehensive access programs. Additional trends include increasing industry involvement, diversification of regulatory approaches, and isolated instances of re-criminalization reflecting policy backlash.

Conclusions and Implications:
Psychedelic policy reform is expanding rapidly across the United States but is proceeding along a more cautious and heterogeneous trajectory than cannabis legalization. For social work, these findings highlight the critical role of policy in shaping access to emerging behavioral health treatments and raise concerns about uneven implementation, potential inequities, and differential access across states and populations. As psychedelic services continue to develop, social work research is essential to inform equitable, evidence-based policy and to ensure that access to novel interventions advances the common good rather than exacerbating existing disparities in mental health care.